Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.
View / Open Files
Authors
Quinn, Kaitlin A
Monti, Sara
Christensen, Robin
Langford, Carol A
Lanier, Georgia E
Mahr, Alfred
Pagnoux, Christian
Shea, Beverley
Tugwell, Peter
Viðarsdóttir, Maria Bjork
Tomasson, Gunnar
Merkel, Peter A
Publication Date
2021-10Journal Title
Semin Arthritis Rheum
ISSN
0049-0172
Publisher
Elsevier BV
Volume
51
Issue
5
Pages
1134-1138
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Quinn, K. A., Monti, S., Christensen, R., Jayne, D., Langford, C. A., Lanier, G. E., Mahr, A., et al. (2021). Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.. Semin Arthritis Rheum, 51 (5), 1134-1138. https://doi.org/10.1016/j.semarthrit.2021.07.001
Abstract
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group aims to develop composite response criteria for ANCA-Associated Vasculitis (AAV). METHODS: The project follows the OMERACT approach for composite measures: (i) choose relevant domains; (ii) define high-quality instruments; (iii) decide on a scoring system approach; (iv) put through the OMERACT Filter 2.1 for validation. RESULTS: A systematic literature review of outcome measures used in clinical trials in AAV and an international Delphi exercise among patients with AAV and clinician-investigators with expertise in AAV have been completed to inform the candidate domains/instruments for the composite response criteria, which are the first two steps in the OMERACT approach for developing composite measures. Results of the systematic literature review and Delphi were presented at the OMERACT 2020 virtual workshop, and feedback was received on the next steps of the project, including the development of a scoring system approach. CONCLUSION: The ultimate goal of this project is to develop validated composite response criteria for use in clinical trials of AAV.
Embargo Lift Date
2022-10-31
Identifiers
External DOI: https://doi.org/10.1016/j.semarthrit.2021.07.001
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330683
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.